Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.

[1]  T. Fleming,et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Kemeny.  Current approaches to metastatic colorectal cancer. , 1994, Seminars in oncology.

[3]  C. Moertel.  Chemotherapy for colorectal cancer. , 1994, The New England journal of medicine.

[4]  J. Dierlamm,et al.  Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Liu,et al.  DNA topoisomerases as anticancer drug targets. , 1990, Advances in pharmacology.

[7]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[8]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Reinberg,et al.  Circadian Changes of Drug Disposition in Man , 1982, Clinical pharmacokinetics.